Cargando…

Mapping the Genetic Interaction Network of PARP inhibitor Response

Genetic interactions have long informed our understanding of the coordinated proteins and pathways that respond to DNA damage in mammalian cells, but systematic interrogation of the genetic network underlying that system has yet to be achieved. Towards this goal, we measured 147,153 pairwise interac...

Descripción completa

Detalles Bibliográficos
Autores principales:	Simpson, Danny, Ling, Jia, Jing, Yangwode, Adamson, Britt
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Cold Spring Harbor Laboratory 2023
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10462155/ https://www.ncbi.nlm.nih.gov/pubmed/37645833 http://dx.doi.org/10.1101/2023.08.19.553986

Ejemplares similares

A Quantitative Chemotherapy Genetic Interaction Map Reveals Factors Associated with PARP Inhibitor Resistance
por: Hu, Hsien-Ming, et al.
Publicado: (2018)

Interactions of PARP1 Inhibitors with PARP1-Nucleosome Complexes
por: Maluchenko, Natalya, et al.
Publicado: (2022)

Revealing biomarkers associated with PARP inhibitors based on genetic interactions in cancer genome
por: Dong, Qi, et al.
Publicado: (2021)

PARP Inhibitors and Proteins Interacting with SLX4
por: Jordheim, Lars Petter
Publicado: (2023)

Serine-linked PARP1 auto-modification controls PARP inhibitor response
por: Prokhorova, Evgeniia, et al.
Publicado: (2021)

HMGB3 promotes PARP inhibitor resistance through interacting with PARP1 in ovarian cancer
por: Ma, Hanlin, et al.
Publicado: (2022)

PARP inhibitors
por: Anwar, Maheen, et al.
Publicado: (2015)

A single nucleotide variant of human PARP1 determines response to PARP inhibitors
por: Cashman, Rivki, et al.
Publicado: (2020)

PARP inhibitors: the race is on
por: Brown, Jessica S, et al.
Publicado: (2016)

PARP Inhibitors in Breast and Ovarian Cancer
por: Wang, Samuel S. Y., et al.
Publicado: (2023)

PARP1 in Carcinomas and PARP1 Inhibitors as Antineoplastic Drugs
por: Wang, Luyao, et al.
Publicado: (2017)

Effect of HO-3089 PARP inhibitor on inflammatory response
por: Nemeth, M, et al.
Publicado: (2011)

CRISPR screens reveal genetic determinants of PARP inhibitor sensitivity and resistance in prostate cancer
por: Tsujino, Takuya, et al.
Publicado: (2023)

PARP inhibitors trap PARP2 and alter the mode of recruitment of PARP2 at DNA damage sites
por: Lin, Xiaohui, et al.
Publicado: (2022)

PARP inhibitors are not all equal
por: Dent, Paul
Publicado: (2013)

PARP inhibitors in ovarian cancer
por: Cibula, David, et al.
Publicado: (2015)

Dual Inhibitors of PARPs and ROCKs
por: Antolín, Albert A., et al.
Publicado: (2018)

Reverse the Resistance to PARP Inhibitors
por: Kim, Yevgeniy, et al.
Publicado: (2017)

Advances and perspectives of PARP inhibitors
por: Yi, Ming, et al.
Publicado: (2019)

Clinical PARP inhibitors allosterically induce PARP2 retention on DNA
por: Langelier, Marie-France, et al.
Publicado: (2023)

Virtual screening for plant PARP inhibitors – what can be learned from human PARP inhibitors?
por: Heym, Peter-Paul, et al.
Publicado: (2012)

PARP1 inhibitors trigger innate immunity via PARP1 trapping-induced DNA damage response
por: Kim, Chiho, et al.
Publicado: (2020)

EZH2 contributes to the response to PARP inhibitors through its PARP-mediated poly-ADP ribosylation in breast cancer
por: Yamaguchi, Hirohito, et al.
Publicado: (2017)

Advancements and Obstacles of PARP Inhibitors in Gastric Cancer
por: Chen, Hongjie, et al.
Publicado: (2023)

Pharmacokinetics and Pharmacodynamics of PARP Inhibitors in Oncology
por: Bruin, Maaike A. C., et al.
Publicado: (2022)

NADP(+) is an endogenous PARP inhibitor in DNA damage response and tumor suppression
por: Bian, Chunjing, et al.
Publicado: (2019)

Response of Breast Cancer Cells to PARP Inhibitors Is Independent of BRCA Status
por: Keung, Man Yee, et al.
Publicado: (2020)

PARP1-SNAI2 transcription axis drives resistance to PARP inhibitor, Talazoparib
por: Ding, Xia, et al.
Publicado: (2022)

Differences in Durability of PARP Inhibition by Clinically Approved PARP Inhibitors: Implications for Combinations and Scheduling
por: Smith, Hannah L., et al.
Publicado: (2022)

The Synergistic Effect of PARP Inhibitors and Immune Checkpoint Inhibitors
por: Wu, Zhaozhen, et al.
Publicado: (2021)

Combinations of PARP Inhibitors with Temozolomide Drive PARP1 Trapping and Apoptosis in Ewing’s Sarcoma
por: Gill, Sonja J., et al.
Publicado: (2015)

Interaction between ATM and PARP-1 in response to DNA damage and sensitization of ATM deficient cells through PARP inhibition
por: Aguilar-Quesada, Rocío, et al.
Publicado: (2007)

Blocking c-Met-mediated PARP1 phosphorylation enhances anti-tumor effects of PARP inhibitors
por: Du, Yi, et al.
Publicado: (2016)

Advances in PARP Inhibitors for Prostate Cancer
por: Tisseverasinghe, Steven, et al.
Publicado: (2023)

PARP inhibitors in metastatic prostate cancer
por: Taylor, Amy K., et al.
Publicado: (2023)

Resistance to PARP-Inhibitors in Cancer Therapy
por: Montoni, Alicia, et al.
Publicado: (2013)

Predicting PARP inhibitor sensitivity and resistance
por: Bebb, D. Gwyn, et al.
Publicado: (2012)

An update on PARP inhibitors for the treatment of cancer
por: Benafif, Sarah, et al.
Publicado: (2015)

Role of Biomarkers in the Development of PARP Inhibitors
por: Ganguly, Bratati, et al.
Publicado: (2016)

In vitro analysis of PARP inhibitor nanoformulations
por: Baldwin, Paige, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_95oeln44hplbbn8vbo9d1cv4cd